HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Actin-Related Protein 2-3 Complex (Arp2 3 Complex)

A complex of seven proteins including ARP2 PROTEIN and ARP3 PROTEIN that plays an essential role in maintenance and assembly of the CYTOSKELETON. Arp2-3 complex binds WASP PROTEIN and existing ACTIN FILAMENTS, and it nucleates the formation of new branch point filaments.
Also Known As:
Arp2 3 Complex; Arp2-3 Protein Complex; Actin Related Protein 2 3 Complex; Arp2 3 Protein Complex; Arp2-3 Complex
Networked: 232 relevant articles (3 outcomes, 17 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Machesky, Laura M: 12 articles (01/2019 - 01/2003)
2. Rottner, Klemens: 8 articles (01/2020 - 10/2002)
3. Insall, Robert H: 7 articles (01/2013 - 09/2003)
4. Faix, Jan: 6 articles (01/2017 - 01/2011)
5. Winterhoff, Moritz: 5 articles (01/2017 - 06/2012)
6. Pollard, Thomas D: 5 articles (02/2015 - 02/2003)
7. Smith, Laurie G: 5 articles (01/2015 - 02/2004)
8. Dyachok, Julia: 5 articles (10/2011 - 11/2004)
9. Pollard, T D: 5 articles (11/2001 - 04/2000)
10. Nolen, Brad J: 4 articles (10/2019 - 05/2011)

Related Diseases

1. Neoplasms (Cancer)
2. Cicatrix (Scar)
3. Neoplasm Metastasis (Metastasis)
4. Hypoxia (Hypoxemia)
01/01/2018 - "Mechanically, we reveal that hypoxia-activated ATM can enhance the binding affinity of cortactin with Arp2/3 complex by phosphorylating cortactin at serine 113, and as a result, in favor of breast cancer cell migration and invasion. "
10/01/2018 - "These include (1) the role of follicular T cells in the differentiation of B cells and development of optimal antibody responses; (2) impaired nuclear factor κB subunit 1 signaling in the pathogenesis of common variable immunodeficiency, revealing an association between impaired B-cell maturation and development of inflammatory conditions; (3) autoimmune and inflammatory manifestations in patients with PIDDs in T- and B-cell deficiencies, as well as in neutrophil disorders; (4) newly described gene defects causing PIDDs, including exostosin-like 3 (EXTL3), TNF-α-induced protein 3 (TNFAIP3 [A20]), actin-related protein 2/3 complex-subunit 1B (ARPC1B), v-Rel avian reticuloendotheliosis viral oncogene homolog A (RELA), hypoxia upregulated 1 (HYOU1), BTB domain and CNC homolog 2 (BACH2), CD70, and CD55; (5) use of rapamycin and the phosphoinositide 3-kinase inhibitor leniolisib to reduce autoimmunity and regulate B-cell function in the activated phosphoinositide 3-kinase δ syndrome; (6) improved outcomes in hematopoietic stem cell transplantation for severe combined immunodeficiency (SCID) in the last decade, with an overall 2-year survival of 90% in part caused by early diagnosis through implementation of universal newborn screening; (7) demonstration of the efficacy of lentiviral vector-mediated gene therapy for patients with adenosine deaminase-deficient SCID; (8) the promise of gene editing for PIDDs using CRISPR/Cas9 and zinc finger nuclease technology for SCID and chronic granulomatous disease; and (9) the efficacy of thymus transplantation in Europe, although associated with an unexpected high incidence of autoimmunity. "
5. Avian Reticuloendotheliosis
10/01/2018 - "These include (1) the role of follicular T cells in the differentiation of B cells and development of optimal antibody responses; (2) impaired nuclear factor κB subunit 1 signaling in the pathogenesis of common variable immunodeficiency, revealing an association between impaired B-cell maturation and development of inflammatory conditions; (3) autoimmune and inflammatory manifestations in patients with PIDDs in T- and B-cell deficiencies, as well as in neutrophil disorders; (4) newly described gene defects causing PIDDs, including exostosin-like 3 (EXTL3), TNF-α-induced protein 3 (TNFAIP3 [A20]), actin-related protein 2/3 complex-subunit 1B (ARPC1B), v-Rel avian reticuloendotheliosis viral oncogene homolog A (RELA), hypoxia upregulated 1 (HYOU1), BTB domain and CNC homolog 2 (BACH2), CD70, and CD55; (5) use of rapamycin and the phosphoinositide 3-kinase inhibitor leniolisib to reduce autoimmunity and regulate B-cell function in the activated phosphoinositide 3-kinase δ syndrome; (6) improved outcomes in hematopoietic stem cell transplantation for severe combined immunodeficiency (SCID) in the last decade, with an overall 2-year survival of 90% in part caused by early diagnosis through implementation of universal newborn screening; (7) demonstration of the efficacy of lentiviral vector-mediated gene therapy for patients with adenosine deaminase-deficient SCID; (8) the promise of gene editing for PIDDs using CRISPR/Cas9 and zinc finger nuclease technology for SCID and chronic granulomatous disease; and (9) the efficacy of thymus transplantation in Europe, although associated with an unexpected high incidence of autoimmunity. "

Related Drugs and Biologics

1. Proteins (Proteins, Gene)
2. Phosphatidylinositols (Phosphatidylinositol)
3. Myosin Type II
4. Sirolimus (Rapamycin)
5. Adenosine Deaminase
6. Actomyosin
7. Zinc Finger Nucleases
8. leniolisib
9. Cortactin
10. Actin Depolymerizing Factors (Cofilins)

Related Therapies and Procedures

1. Hematopoietic Stem Cell Transplantation
2. Transplantation
3. Therapeutics
4. Traction
5. Lasers (Laser)